Trials / Completed
CompletedNCT00086034
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (planned)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Motexafin gadolinium |
Timeline
- First posted
- 2004-06-23
- Last updated
- 2007-05-15
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00086034. Inclusion in this directory is not an endorsement.